- In its Q4 13F, activist investor Sarissa Capital discloses it has a 5.05M-share (3.3%) stake in Idenix Pharmaceuticals (IDIX +1.8%). Shares initially jumped on the disclosure, but have quickly given back some of their gains.
- Last year, Sarissa took part in a successful proxy battle against Vivus. The firm now has Ariad Pharmaceuticals in its sights.
at CNBC.com (Aug 25, 2014)